| Symbol | CTNM |
|---|---|
| Name | CONTINEUM THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 10578 SCIENCE CENTER DRIVE,SUITE 200, SAN DIEGO, California, 92121, United States |
| Telephone | (858) 333-5280 |
| Fax | — |
| — | |
| Website | https://www.contineum-tx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001855175 |
| Description | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California. Additional info from NASDAQ: |
Director Stengone Carmine N. 🟡 adjusted position in 2.5K shares (1 derivative) of Contineum Therapeutics, Inc. (CTNM) at $16.01 Transaction Date: Aug 03, 2026 | Filing ID: 052031
Read more📋 CARMINE STENGONE (Director) plans to sell 2K shares of Contineum Therapeutics, Inc. (at $15.49 each, total $39K) Filed: Aug 03, 2026 | ID: 007517
Read more📋 Daniel Lorrain (Officer) plans to sell 10K shares of CONTINEUM THERAPEUTIC INC (at $15.49 each, total $147K) Filed: Aug 03, 2026 | ID: 007509
Read more(30% Negative) CONTINEUM THERAPEUTICS, INC. (CTNM) Reports Q3 2026 Financial Results
Read moreContineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Read moreNew Form SCHEDULE 13G/A - Contineum Therapeutics, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001104659-26-084693 <b>Size:</b> 16 KB
Read moreLorrain Daniel S. 🟡 adjusted position in 37.2K shares (2 derivative) of Contineum Therapeutics, Inc. (CTNM) at $16.24 Transaction Date: Jun 30, 2026 | Filing ID: 047058
Read moreContineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Read moreDirector Miralles Gines Diego 🟢 acquired 19.0K shares (1 derivative) of Contineum Therapeutics, Inc. (CTNM) at $14.19 Transaction Date: Jun 26, 2026 | Filing ID: 045845
Read moreDirector Lyons-Williams Lori 🟢 acquired 19.0K shares (1 derivative) of Contineum Therapeutics, Inc. (CTNM) at $14.19 Transaction Date: Jun 26, 2026 | Filing ID: 045843
Read more